Supply disruptions for Ziflucort have been reported in Russia. This vital medication is essential for adrenal dysfunction.
In the first half of March alone, sales fell by half. Many popular pharmacy chains, including Rigla, 36,6, and Planeta Zdorovya, are completely out of stock. This may be due to the low maximum price for Ziflucort—the sole manufacturer has no incentive to increase production, Kommersant's sources believe.
However, the Pharmasyntez group of companies claims that new batches entered circulation on March 2, and that delays at pharmacies are due to logistics and increased demand. Roszdravnadzor also confirms there is no shortage: as of March 16, 73 packages of Ziflucort remained in stock, according to Roszdravnadzor officials.
Ziflucort is used to compensate for hormone deficiencies that occur when the adrenal glands are dysfunctional. It is regularly taken, for example, by patients with Addison's disease, adrenogenital syndrome, or those who have had their adrenal glands removed for other reasons. The drug is listed as essential and is provided free of charge to eligible citizens.
According to DSM Group, 97,9 packages of Ziflucort were sold in Russian pharmacies and through government procurement in 2025. This represents a 42,9% increase compared to 2024.
NeMoskva regularly reports on supply disruptions of vital medications in Russia. For example, in several regions there is a shortage of Parsabiv, a drug used to treat kidney disease. In August, there was a shortage of subsidized medications for patients with diabetes, asthma, and cancer. And in June, Yakutia It was impossible to even buy saline solution.

Photo: Ammoniac